Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
43.02
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jun 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
November 09, 2022
From
Bristol Myers Squibb
Via
Business Wire
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
November 02, 2022
From
Bristol Myers Squibb
Via
Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
October 31, 2022
From
Bristol Myers Squibb
Via
Business Wire
MarketBeat: Week in Review 10/24-10/28
October 29, 2022
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Economy
Electric Vehicles
Interest Rates
Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value
October 27, 2022
Bristol Myers Squibb stock posts results that establish it as an attractive value stock, even if it may not be as undervalued as it appeared before.
Via
MarketBeat
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
October 26, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
October 25, 2022
From
Bristol Myers Squibb
Via
Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
October 25, 2022
From
Bristol Myers Squibb
Via
Business Wire
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
October 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
October 21, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
October 19, 2022
From
Bristol Myers Squibb
Via
Business Wire
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
October 07, 2022
From
Bristol Myers Squibb
Via
Business Wire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
September 16, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
September 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 14, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
September 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
September 09, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
September 07, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
September 07, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
September 05, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
August 31, 2022
From
Bristol Myers Squibb
Via
Business Wire
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
August 28, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
August 17, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
August 16, 2022
From
Bristol Myers Squibb
Via
Business Wire
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
August 10, 2022
Via
Investor Brand Network
Exposures
Product Safety
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
August 10, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...
Via
FinancialNewsMedia
Exposures
Product Safety
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.